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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus known to establish lifelong latency in the human host.
We and others have previously shown that three KSHV homologs of cellular interferon regulatory factors (IRFs), known as viral
IRFs (vIRFs), participate in evasion of the host interferon (IFN) response. We report that vIRF1 interacts with the cellular inter-
feron-stimulated gene 15 (ISG15) E3 ligase, HERC5, in the context of Toll-like receptor 3 (TLR3) activation and IFN induction.
The ISG15 protein is covalently conjugated to target proteins upon activation of the interferon response. Interaction between
vIRF1 and HERC5 was confirmed by immunoprecipitation, and the region between amino acids 224 and 349 of vIRF1 was re-
quired for interaction with HERC5. We further report that expression of vIRF1 in the context of TLR3 activation results in de-
creased ISG15 conjugation of proteins. Specifically, TLR3-induced ISG15 conjugation and protein levels of cellular IRF3, a
known ISG15 target, were decreased in the presence of vIRF1 compared to the control. vIRF1 itself was also identified as a target
of ISG15 conjugation. KSHV-infected cells exhibited increased ISG15 conjugation upon reactivation from latency in coordina-
tion with increased IFN. Furthermore, knockdown of ISG15 in latently infected cells resulted in a higher level of KSHV reactiva-
tion and an increase in infectious virus. These data suggest that the KSHV vIRF1 protein affects ISG15 conjugation and inter-
feron responses and may contribute to effective KSHV replication.
IMPORTANCE
The KSHV vIRF1 protein can inhibit interferon activation in response to viral infection. We identified a cellular protein named
HERC5, which is the major ligase for ISG15, as a vIRF1 binding partner. vIRF1 association with HERC5 altered ISG15 modifica-
tion of cellular proteins, and knockdown of ISG15 augmented reactivation of KSHV from latency.
Upon detection of viral infection, cells activate the quintessen-tial antiviral immune response, which results in production
of type I interferon (IFN), including interferon alpha (IFN-) and
IFN-. Type I IFN induces an antiviral transcriptional program,
producing proteins that cooperate to inhibit the spread of infec-
tion. One of the most abundantly produced transcripts upon in-
duction of the type I IFN response is interferon-stimulated gene
15 (ISG15) (1, 2). ISG15 is a ubiquitin-like 17-kDa protein that
is covalently conjugated to target proteins via a process called
ISGylation (3–5). Similar to ubiquitin, ISG15 requires three enzy-
matic steps for conjugation onto target proteins. They include the
E1 enzyme Ube1L, the conjugating E2 enzyme UbcH8, and the
major E3 ligase HERC5 (6). Multiple large-scale screens have
identified hundreds of potential cellular targets of ISGylation;
however, in most cases, the specific function of ISG15 conjugation
to cellular proteins remains undetermined (7).
Thus far, identified ISG15 target proteins function in a variety
of cellular pathways, including glycolysis, cell motility, transla-
tion, and stress responses, with the most studied ISG15 targets
lying within the type I IFN pathway. ISG15 targets in the IFN
pathway include protein kinase R (PKR), retinoic acid-inducible
gene 1 (RIG-I), signal transducer and activator of transcription 1
(STAT1), and cellular interferon regulatory factor 3 (IRF3) (7).
The IRF3 transcription factor is activated upon detection of a
pathogen and is in part responsible for transcription and produc-
tion of type I IFNs. Additionally, IRF3 is ISGylated on lysine res-
idues 193, 360, and 366 (8). When IRF3 is not ISGylated, IRF3
interacts more tightly with Pin1, resulting in increased polyubiq-
uitination and IRF3 degradation (8). While the specific function
of ISGylation on many other target proteins remains to be clari-
fied, it is clear that ISG15 plays a crucial role in antiviral immunity.
ISG15 conjugation has been found to inhibit the growth of influ-
enza A and B virus, Ebola virus, Sindbis virus, HIV, and herpes
simplex virus 1 (HSV-1), among others (9). In contrast, vesicular
stomatitis virus (VSV) and lymphocytic choriomeningitis virus
(LCMV) do not seem to be inhibited by ISG15 conjugation (10).
To date, the only gammaherpesvirus that has been examined for a
correlation between ISG15 expression and viral replication is mu-
rine gammaherpesvirus 68 (MHV-68). Infection of ISG15 knock-
out mice exhibited a 10-fold increase in MHV-68 viral titers, al-
though no change in viral lethality was observed (11). The
relationship between the human gammaherpesvirus Kaposi’s sar-
coma-associated herpesvirus (KSHV) and ISG15 has not been
previously investigated.
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KSHV is a double-stranded DNA virus and the etiological
agent for Kaposi’s sarcoma, an endothelial-cell-driven cancer
(12). KSHV also contributes to two different lymphoproliferative
disorders: primary effusion lymphoma (PEL) and multicentric
Castleman’s disease (MCD) (13, 14). Like all herpesviruses, KSHV
establishes lifelong latent infection and, in order to do so, must
evade host immune responses, including the type I IFN response.
KSHV encodes four viral homologs of cellular interferon regula-
tory factors (vIRF1, -2, -3, and -4) with pleiotropic effects, includ-
ing evasion of cell death, increased proliferation, and evasion of
immune responses (15). Our previous work examined how KSHV
vIRF1, -2, and -3 modulated Toll-like receptor 3 (TLR3)-medi-
ated IFN production (16). We found that expression of vIRF1 and
vIRF2 inhibited increases in IFN- mediated by TLR3 (16), a
pathogen-associated molecular pattern receptor that is upregu-
lated in response to KSHV infection (17).
To further elucidate the mechanisms of KSHV and vIRF1 in-
hibition of type I IFN, we performed an unbiased analysis to dis-
cover novel cellular protein interactions with KSHV vIRF1 in the
context of TLR3 activation and identified the cellular ISG15 E3
ligase, HERC5. Expression of vIRF1 resulted in a global decrease
in ISGylation of target proteins. Additionally, ISG15 conjugation
increased in latently infected cells following reactivation, and we
found that knockdown of ISG15 allowed increased viral reactiva-
tion compared to a scrambled control. Collectively, these data
suggest that modulation of the ISG15 pathway by KSHV vIRF1
may inhibit host immune responses and represent a mechanism
through which KSHV evades IFN responses to establish and main-
tain lifelong infection of the human host.
MATERIALS AND METHODS
Plasmids. pcDNA3 Ube1L, UbcH8, HA-HERC5, HIS6-HA-ISG15, and
HIS6-3FLAG-ISG15 (18, 19) were generous gifts of Robert Krug (Uni-
versity of Texas at Austin, Austin, TX). pcDNA3 HERC5 (without an
epitope tag) was produced with a QuikChange XL II site-directed mu-
tagenesis kit (Agilent). pcDNA3 Myc-vIRF1 was a generous gift from Jae
Jung (University of Southern California, Los Angeles, CA). Myc-vIRF1
was cloned into pLenti CMV Puro DEST (w118-1; Addgene) via pENTR
TOPO and the Gateway system (Invitrogen). 3FLAG-vIRF1 was codon
optimized and generated by Genescript and cloned into pcDNA3.1. De-
letion mutants of vIRF1 were amplified from the codon-optimized con-
struct and cloned with a pcDNA3.1 Directional TOPO Expression kit
(Invitrogen). Mission short hairpin RNA (shRNA) constructs for ISG15
and HERC5 were purchased (Sigma).
Cell culture. 293 cells were cultured at 37°C with 5% CO2 in Dulbec-
co’s modified Eagle medium (DMEM) (Cellgro) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Cellgro), 100 U/ml (each) of
penicillin and streptomycin, and 2 mM L-glutamine. 293-TLR3 cells (In-
vivoGen) were maintained in 10 g/ml Blasticidin S (InvivoGen). TREx
BCBL1 inducible cells expressing either empty vector (EV) or replication
and transcription activator (RTA) protein (20) were cultured in RPMI
1640 medium (Corning) containing tetracycline -free FBS (Clontech) and
20 g/ml hygromycin B (Roche). BCBL1 PEL cells were cultured in RPMI
1640 medium (Corning) containing 0.05 mM -mercaptoethanol.
iSLK.219 cells harboring latent recombinant KSHV.219 (rKSHV.219)
(21) were maintained in DMEM supplemented with 10% FBS (Cellgro),
1% penicillin and streptomycin, G418 (250 g/ml), hygromycin (400
g/ml), and puromycin (10 g/ml).
293-TLR3 cells were transfected with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The cells were transfected
with twice as much HERC5 and ISG15 as Ube1L and UbcH8, as previously
reported (22). To activate TLR3 signaling, cells were treated with high-
molecular-weight poly(I·C) (Invivogen) at 20 g/ml for 24 h. TREx
BCBL1 cells were reactivated with 1 g/ml doxycycline for the times in-
dicated. BCBL1 PEL cells were reactivated with 1 mM sodium butyrate
and 25 ng/ml 12-O-tetradecanoyl-phorbol 13-acetate (TPA) where indi-
cated. iSLK.219 cells were reactivated with 0.1 g/ml doxycycline.
Immunoprecipitation and immunoblotting. For mass spectrometry,
10-cm2 dishes were seeded with 1.25  106 293-TLR3 cells, and after
equilibration overnight, the cells were transfected for 36 h with 20 g
pcDNA3.1 3FLAG-vIRF1, after which the cells were stimulated for 24 h
with either poly(I·C) (Invivogen) or vehicle control. After stimulation, the
cells were lysed, and FLAG affinity purification was performed according
to the manufacturer’s instructions (Sigma). The pulldown products were
run on a 10% SDS gel and subjected to silver staining according to the
manufacturer’s suggestions (Invitrogen). Bands of interest were excised
and submitted to the Taplin Mass Spectrometry Facility (Harvard Uni-
versity).
For immunoprecipitation assays, equal amounts of protein were pre-
cleared with the appropriate IgG antibody (normal mouse IgG; Santa
Cruz), followed by overnight incubation with FLAG or hemagglutinin
(HA) antibody-conjugated beads (EZview Red Anti-FLAG M2 Affinity
Gel or EZveiw Red Anti-HA Affinity Gel; Sigma). The beads were washed
3 times with lysis buffer, and the bound proteins were released through
competitive elution with 150 ng/l 3 FLAG peptide (Sigma) or 100
g/ml influenza virus HA peptide (Sigma) during a 1-h incubation. The
supernatants were separated from the beads prior to addition of SDS
loading dye and immunoblotting.
For immunoblotting, cells were washed once with PBS and lysed in
0.1% NP-40 with the addition of protease inhibitor complete tabs
(Roche). The protein concentration was determined by Bradford assay
(Bio-Rad), and equal amounts of proteins were separated using SDS-
PAGE and transferred onto Hybond-ECL nitrocellulose membranes (GE
Healthcare). The antibodies used included anti-Myc-horseradish peroxi-
dase (HRP) (Invitrogen), anti-enterokinase cleavage site (xxxDDDDK)-
HRP (Bethyl), anti-ISG15 (Cell Signaling), anti-IRF3 (Cell Signaling),
anti-HA-HRP (Cell Signaling), anti-tubulin-HRP (Cell Signaling), anti-
Ku70/80 (a generous gift from Dale Ramsden, University of North Caro-
lina, Chapel Hill, NC), and anti-actin (Santa Cruz). The blots were ex-
posed to appropriate secondary antibodies conjugated to horseradish
peroxidase when necessary and visualized using SuperSignal West Pico
(Pierce), Clarity (Bio-Rad), or Amersham Prime ECL Western blotting
detection reagent (GE).
Lentiviral transduction. pLenti Myc-vIRF1 and mission shRNA con-
structs for ISG15 and HERC5 were used to generate lentivirus-expressing
vIRF1 or shRNAs via the ViraPower system (Invitrogen), according to the
manufacturer’s instructions. Briefly, 293T cells were transfected with 3 g
of shRNA construct and 9 g of ViraPower packing mix. The transfection
medium was replaced with antibiotic-free medium 4 h posttransfection;
48 h posttransfection, the medium was harvested and spun at 3,000 rpm
for 15 min and stored in aliquots at 80°C. To transduce iSLK.219 cells, 2
ml of lentiviral supernatant was applied to the cells in conjunction with 10
g/ml Polybrene (Sigma), and the cells were centrifuged at 2,500 rpm for
90 min at 32°C. Following transduction, 2 ml of complete medium was
added to the cells. To transduce BCBL1 cells, 4 million cells were resus-
pended in 4 ml of lentiviral supernatant with 10 g/ml Polybrene (Sigma)
and centrifuged at 2,500 rpm for 90 min at 32°C. The lentiviral superna-
tant was removed, and the cells were resuspended in standard PEL me-
dium for 24 h. Then, the cells were infected a second time in the same
manner with 2 ml of lentiviral supernatant.
Quantitation of viral reactivation via real-time PCR or microscopy.
DNA was isolated with a DNeasy blood and tissue kit (Qiagen) according
to the manufacturer’s instructions. RNA was isolated using an RNeasy
Plus minikit or an RNeasy Micro kit (Qiagen), and reverse transcription
was performed using SuperScript III reverse transcriptase (Invitrogen)
and oligo(dT) (Invitrogen). Real-time PCR was performed on an ABI
7300 using SYBR green PCR master mix (Bio-Rad). The PCR was carried
out with 1 cycle of 50°C for 2 min and 95°C for 10 min, followed by 40
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cycles of 95°C for 15 s and 60°C for 1 min. All fold activations were
normalized to -actin. The primer sequences used were as follows: -Ac-
tin Forward, 5=-TCATGAAGTGTGACGTGGACATC, and Reverse, 5=-C
AGGAGGAGCAATGATCTTGATCT (23); Orf57 Forward, 5=-TGGACA
TTATGAAGGGCATCCT, and Reverse, 5= –CGGGTTCGGACAATT
GCT; IFN- Forward, 5=-GTGAGGAAATACTTCCAAAGAATCAC, and
Reverse, 5=-TCTCATGATTTCTGCTCTGACAA; and IFN- Forward,
5=-CAGCAATTTTCAGTGTCAGAAGC, and Reverse, 5=-TCATCCT
GTCCTTGAGGCAGT.
To determine levels of KSHV infection (green fluorescent protein
[GFP]) or KSHV reactivation to the lytic state (red fluorescent protein
[RFP]), cells were examined with a Nikon Eclipse Ti microscope using
Nikon Elements software.
RESULTS
vIRF1 interacts with the ISG15 E3 ligase HERC5. To identify
vIRF1 functional roles in an unbiased manner, we sought to find
novel cellular interacting proteins using a system in which vIRF1
was previously shown to inhibit IFN responses (16). To this end,
293-TLR3 stable expressing cells were transfected for 36 h with
vIRF1-FLAG constructs and stimulated for 24 h with poly(I·C), a
double-stranded RNA analogue and ligand for TLR3. After stim-
ulation, FLAG affinity purification was performed, the products
were separated via PAGE, and the gel was silver stained. Bands
were excised and subjected to mass spectrometry. The results in-
dicated that vIRF1 associated with CREBBP and p300, as previ-
ously reported (24, 25), in the presence or absence of poly(I·C)
(Fig. 1A). However, only in the context of TLR3 activation with
poly(I·C) did we find that vIRF1 coimmunoprecipitated with
HERC5, the E3 ligase for ISG15.
To confirm the interaction between vIRF1 and HERC5, 293-
TLR3 cells were transfected with equal concentrations of FLAG-
vIRF1 or EV control and HA-HERC5 plasmids. HERC5 was im-
munoprecipitated with anti-HA antibody-conjugated beads, and
HERC5-bound proteins were eluted with HA peptide. The eluate
and input samples were resolved via SDS-PAGE and subjected to
immunoblotting with an anti-FLAG antibody to detect vIRF1.
This experiment showed that HERC5 and vIRF1 coimmunopre-
cipitate (Fig. 1B), and we confirmed this interaction with reverse
immunoprecipitation, in which vIRF1 protein was captured using
FLAG antibody-conjugated beads. Proteins were eluted with 3
FLAG peptide, and eluate and input samples were resolved via
SDS-PAGE and subjected to immunoblotting with an anti-HA
antibody. This immunoprecipitation also demonstrated an asso-
ciation between HERC5 and vIRF1 (Fig. 1C). These data indicate
that KSHV vIRF1 associates with the ISG15 E3 ligase, HERC5.
HERC5 interacts with the C-terminal region of vIRF1. As
HERC5 was found to associate with vIRF1, we next sought to
determine which portion of vIRF1 is required for the interaction
between vIRF1 and HERC5. Two C-terminal deletion mutants of
vIRF1, one containing only amino acids (aa) 1 to 349 and one
containing only aa 1 to 224, were generated to compare to the
full-length (FL) 449-aa vIRF1 (Fig. 2A). To determine the portion
of vIRF1 required for binding to HERC5, 293-TLR3 cells were
transfected with HA-HERC5 or control vector and either the FL or
the aa 1 to 349 or aa 1 to 224 mutant FLAG-vIRF1 construct. The
cell lysates were immunoprecipitated with FLAG antibody-conju-
gated beads and eluate, and input samples were subjected to SDS-
PAGE and immunoblotted with anti-HA antibody to visualize
HERC5. As shown in Fig. 2B, only FL and aa 1 to 349 vIRF1 were
capable of binding to HERC5, while aa 1 to 224 vIRF1 did not
demonstrate an association with HERC5. To confirm this result,
the reverse immunoprecipitation was performed. 293-TLR3 cells
were transfected with the FL or the aa 1 to 349 or aa 1 to 224
mutant FLAG-vIRF1 construct or control vector and HA-HERC5.
The cell lysates were immunoprecipitated with anti-HA antibody,
and eluates and input samples were resolved via SDS-PAGE. Im-
munoblotting with anti-FLAG antibodies was performed to detect
vIRF1. As seen previously, only FL vIRF1 and the aa 1 to 349 vIRF1
mutant were capable of interacting with HERC5 (Fig. 2C). These
data suggest that the region of vIRF1 between amino acids 224 and
349 interacts with HERC5.
vIRF1 expression decreases total cellular ISG15 conjugation
to proteins. We demonstrated that vIRF1 associates with the
ISG15 E3 ligase HERC5; however, the functional significance of
this interaction remained unclear. To address this, the effect of
vIRF1 expression on global ISG15 conjugation was examined.
293-TLR3 cells were transfected with constructs expressing ISG15
FIG 1 KSHV vIRF1 binds to cellular HERC5 in the context of TLR3 activa-
tion. (A) 293-TLR3 stable expressing cells were transfected for 36 h with
vIRF1-FLAG and stimulated for 24 h with poly(I·C) (pI:C). After stimulation,
FLAG affinity purification was performed, and the products were separated via
PAGE and silver stained. Bands of interest were excised and subjected to mass
spectrometry. Selected results for proteins interacting with KSHV vIRF1 with
or without treatment with poly(I·C) are shown. (B) 293-TLR3 cells were trans-
fected with HA-HERC5 and control EV or FLAG-vIRF1 plasmids. Twenty-
four hours after transfection, the cells were treated with poly(I·C) and har-
vested 24 h after treatment. The cell lysates were immunoprecipitated (IP) with
anti-HA antibody-conjugated beads; resolved by SDS-PAGE, along with input
control lysates; and probed with antibodies as indicated. (C) 293-TLR3 cells
were transfected with FLAG-vIRF1 and control EV or HA-HERC5 plasmid.
Twenty-four hours after transfection, the cells were treated with poly(I·C) and
harvested 24 h after treatment. The cell lysates were immunoprecipitated with
anti-FLAG antibody-conjugated beads and were subjected to SDS-PAGE
along with a fraction of the input lysates, and immunoblotting was performed
with various antibodies as indicated. The data are representative of the results
of more than four independent experiments.
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and its accompanying E1, E2, and E3 ligases and different ratios of
control EV or vIRF1. Cells received 0 g, 1 g, or 4 g of vIRF1
plasmid DNA, and EV plasmid was added to keep the total
amount of transfected DNA at 4 g for each sample. One day
posttransfection, the cells received poly(I·C) to stimulate TLR3-
mediated type I interferon production, ISG15 production, and
ISG15 conjugation (2). Regardless of poly(I·C) treatment, cells
that received 4 g of vIRF1 construct demonstrated a decreased
level of ISGylation of target proteins compared to cells that re-
ceived 1 g of vIRF1 plasmid DNA (Fig. 3A). Furthermore, cells
that received only 1 g of vIRF1 exhibited decreased ISG15 con-
jugation compared to cells that did not express vIRF1. These data
indicate that expression of vIRF1 may serve to block the normal
conjugation and function of ISG15.
We hypothesized that vIRF1 interaction with HERC5 may be
FIG 2 vIRF1 interacts with HERC5 between amino acids 224 and 349. (A)
Two vIRF1 truncation mutants and full-length (FL) vIRF1. The black squares
indicate the location of the FLAG tag. DBD, DNA-binding domain; IAD, IRF
association domain. (B) 293-TLR3 cells were transfected with HA-HERC5 or
control vector () and FL or aa 1 to 349 or aa 1 to 224 mutant FLAG-vIRF1
constructs. Twenty-four hours after transfection, the cells were treated with
poly(I·C) and harvested 24 h after treatment. The cell lysates were immuno-
precipitated with FLAG antibody-conjugated beads. Eluate and input samples
were subjected to SDS-PAGE and immunoblotted as indicated. (C) 293-TLR3
cells were transfected with FL or aa 1 to 349 or aa 1 to 224 mutant FLAG-vIRF1
constructs or control vector () and HA-HERC5. Twenty-four hours after
transfection, the cells were treated with poly(I·C) and harvested 24 h posttreat-
ment. The cell lysates were immunoprecipitated with anti-HA antibody-con-
jugated beads prior to resolution with SDS-PAGE and immunoblotting with
the indicated antibodies. The data are representative of the results of three
independent experiments.
FIG 3 vIRF1 decreases conjugation of ISG15 to cellular proteins in the context
of TLR3 activation. (A) 293-TLR3 cells were transfected with 0, 1, or 4 g of
FLAG-vIRF1 and control EV to a total of 4 g DNA. The cells were also
transfected with the E1, E2, and E3 ligases for ISG15, as well an ISG15 con-
struct. Twenty-four hours after transfection, the cells were treated with
poly(I·C) as indicated and harvested 24 h after treatment. The cell lysates were
subjected to SDS-PAGE and immunoblotting and probed with antibodies as
indicated. (B) 293-TLR3 cells were transfected with FL or aa 1 to 349 or aa 1 to
224 mutant FLAG-vIRF1 constructs and the E1, E2, and E3 ligases for ISG15
and HA-ISG15. Twenty-four hours after transfection, the cells were treated
with poly(I·C) and harvested 24 h posttreatment. The cell lysates were sub-
jected to SDS-PAGE, followed by immunoblotting with the antibodies indi-
cated. The data are representative of the results of three independent experi-
ments.
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required for vIRF1-mediated alterations in the ISGylation of cel-
lular proteins. To determine the importance of the vIRF1 and
HERC5 association in altering ISG15 conjugation of target pro-
teins, 293-TLR3 cells were transfected with constructs expressing
ISG15 and its accompanying E1, E2, and E3 ligases and equal
amounts of EV or FL, aa 1 to 349, or aa 1 to 224 mutant vIRF1
plasmid. The cells were treated with poly(I·C) to induce ISG15
conjugation, followed by cell lysis, SDS-PAGE, and immunoblot-
ting with an anti-ISG15 antibody to assess ISGylation levels. As
seen previously, expression of FL vIRF1 resulted in decreased lev-
els of ISG15 compared to EV, and expression of the aa 1 to 349
mutant exhibited levels of ISG15 conjugation similar to that of FL
vIRF1 (Fig. 3B). However, the aa 1 to 224 mutant vIRF1 sample
showed the same degree of ISGylation as EV and more than that
seen in the FL and aa 1 to 349 vIRF1 samples. These data suggest
that vIRF1 expression alters the amount of ISG15 conjugation to
target proteins and that the interaction between vIRF1 and
HERC5 is necessary for this blockade.
vIRF1 expression decreases protein levels of IRF3 in the con-
text of TLR3 activation. Expression of vIRF1 resulted in decreased
levels of ISG15 conjugation on cellular target proteins. Therefore,
we examined the consequences of vIRF1 expression for specific
targets of ISGylation. Many signaling molecules involved in the
IFN response have been identified as ISG15 targets (7), and as
vIRF1 is known to inhibit the IFN response (15), this area became
the focus of our studies. Specifically, cellular IRF3, required for
maximal transcription of IFN, associates with HERC5 and is
ISGylated (8). IRF3 was also of interest, as our previous report
indicated that vIRF1 expression led to decreased phosphorylation
of IRF3 and was correlated with a significant reduction in inter-
feron production (16). To determine the effect of vIRF1 expres-
sion on IRF3 protein levels in the context of TLR3 activation,
293-TLR3 cells were transfected with constructs expressing ISG15
and its accompanying E1, E2, and E3 ligases or EV control, and
vIRF1 or EV control. After transfection, half of the samples were
treated with poly(I·C) to activate the IFN response. The cells were
then lysed and subjected to SDS-PAGE analysis and immuno-
blotted with antibodies that recognize endogenous IRF3 and
ISG15. In cells that did not exogenously express the ISG15 path-
way components, ISG15 conjugation of target proteins could not
be detected (Fig. 4A), as reported previously (18, 19). As shown
above, ISGylation of target proteins was increased following
poly(I·C) stimulation compared to untreated cells, and expression
of vIRF1 resulted in decreased ISG15 conjugation compared to
EV. Importantly, in the context of poly(I·C) stimulation, IRF3
protein levels were reduced in the presence of vIRF1 compared to
EV (Fig. 4A). It has previously been reported that ISGylation of
IRF3 stabilizes the protein compared to an IRF3 mutant that can-
not be ISGylated (8). The decrease in IRF3 protein levels corre-
lated with decreased ISG15 conjugation of cellular genes, suggest-
ing that one potential function of vIRF1 interaction with HERC5
may be to decrease ISGylation of IRF3 and thus decrease IRF3
protein stability and IRF3 transcription of IFN-stimulated genes.
To confirm that IRF3 was ISGylated in our system, 293-TLR3
cells were transfected with constructs expressing FLAG-ISG15 and
its accompanying E1, E2, and E3 ligases and EV control or Myc
epitope-tagged vIRF1. The cells were then treated with poly(I·C)
for 24 h. Cells were harvested, and the lysates were incubated with
anti-FLAG antibody-conjugated beads to immunoprecipitate
FLAG-ISG15 and ISG15-conjugated proteins. The resulting elu-
ates and input samples were resolved via SDS-PAGE and immu-
noblotted with antibodies against IRF3 to compare the amount of
ISGylated IRF3 in EV-expressing cells to that in vIRF1-expressing
cells. More ISGylated IRF3 immunoprecipitated with the ISG15
antibody in EV-expressing cells than in vIRF1-expressing cells
(Fig. 4B). This suggested that vIRF1 expression resulted in de-
creased ISGylation of IRF3 and, together with Fig. 4A, suggests
that decreased ISG15 conjugation of IRF3 results in decreased
IRF3 protein levels, which is consistent with previous reports (8).
KSHV vIRF1 is ISG15 conjugated. Surprisingly, examination
of vIRF1 after immunoprecipitation with an anti-ISG15 antibody
FIG 4 vIRF1 expression decreases protein levels of IRF3 following TLR3 ac-
tivation. (A) 293-TLR3 cells were transfected with expression plasmids for E1,
E2, and E3 ligases for ISG15 and ISG15 where indicated. The cells were also
transfected with constructs of FLAG-vIRF1 or control EV. Twenty-four hours
after transfection, the cells were treated with poly(I·C) as indicated and har-
vested 24 h after treatment. The cells were lysed, resolved via SDS-PAGE, and
subjected to immunoblotting with the antibodies indicated. (B) 293-TLR3
cells were transfected with the E1, E2, and E3 ligases for ISG15 and FLAG-
ISG15 and Myc-vIRF1 or control EV. Twenty-four hours after transfection,
the cells were treated with poly(I·C) and harvested 24 h after treatment. The
cells were lysed and immunoprecipitated with anti-FLAG antibody-conju-
gated beads prior to SDS-PAGE and immunoblotting with the indicated anti-
bodies. The data are representative of the results of more than five independent
experiments.
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indicated that vIRF1 was conjugated to ISG15. Furthermore, a
higher-molecular-weight form of vIRF1 was visible after electro-
phoresis (Fig. 4B). This suggested that vIRF1 may itself be conju-
gated to ISG15. Other viral proteins are known to be ISGylated,
including NS1A of influenza virus (26). To test the ISG15 conju-
gation of vIRF1, 293-TLR3 cells were transfected with the E1, E2,
and E3 ligases for ISG15, FLAG-ISG15, and Myc-vIRF1 or control
empty vector. The cell lysates were immunoprecipitated with anti-
FLAG antibody-conjugated beads, bound proteins were eluted
with 3 FLAG peptide, and the resultant eluates and input sam-
ples were subjected to SDS-PAGE prior to immunoblotting with
anti-Myc antibodies to detect vIRF1. Our data indicated that
vIRF1 is conjugated to ISG15 (Fig. 5A). Multiple forms of vIRF1
that appeared to be larger than canonical vIRF1 were visible in the
immunoprecipitation eluates, suggesting that vIRF1 is ISGylated
at multiple sites.
To confirm this finding, reverse immunoprecipitation was also
performed. After transfection with E1, E2, and E3 ligases for
ISG15, FLAG-vIRF1, and HA-ISG15 or control empty vector, cells
were lysed and incubated with anti-FLAG antibody-conjugated
beads to isolate FLAG-vIRF1 and interacting partners. Eluates and
input samples were resolved via SDS-PAGE and immunoblotted
with anti-HA antibody to visualize ISG15. Again, more than one
band of ISG15 was visible, suggesting covalent conjugation of
ISG15 to vIRF1 (Fig. 5B). Together, these data indicate that vIRF1
is conjugated to ISG15 during TLR3 activation.
Reactivation of KSHV from latency results in induction of
IFN and increased ISGylation. The interaction between HERC5
and vIRF1 seems to inhibit the ISG15 pathway and may play a role
in vIRF1 blockade of the IFN response. To assess normal ISG15
activity in the context of the whole virus, we employed a latent
model of infection for reactivation of KSHV. Specifically, we uti-
lized TREx BCBL1 PEL cells with an inducible empty vector (pc)
or inducible replication and transcription activator protein
(RTA), the major viral-lytic-switch protein of KSHV (20). The
TREx cells were treated with doxycycline to activate RTA for var-
ious lengths of time, and cells were harvested and examined for
expression of endogenous ISG15 by SDS-PAGE and immunoblot-
ting. KSHV reactivation correlated with increased conjugation of
ISG15, which peaked 24 h after reactivation, and the levels re-
mained elevated 48 h after reactivation (Fig. 6A). Reactivation of
TREx cells with inducible RTA expression also resulted in in-
creased IFN- and IFN- message levels at 24 and 48 h compared
to nonreactivated cells (Fig. 6B).
To further examine the role of ISG15 during KSHV reactivation,
normal BCBL1 PEL cells were reactivated with sodium butyrate for
24 or 48 h. The cells were harvested, and the lysates were separated via
SDS-PAGE and probed for endogenous ISG15 expression. Similar to
our observation in the inducible RTA system, an increase in ISG15
conjugation following KSHV reactivation was seen in the BCBL1 cells
(Fig. 6C). As expected, reactivation of KSHV in BCBL1 cells resulted
in increased IFN- and IFN- message levels (Fig. 6D). Together,
these data suggest that the switch from latency to the lytic cycle acti-
vates the interferon pathway and induces ISG15 conjugation and that
these processes are tightly correlated.
vIRF1 expression in PEL cells alters ISGylation and KSHV
reactivation. To specifically address the role of vIRF1 on ISG15
during reactivation of PEL cells, BCBL1 cells were transduced with
a vIRF1-expressing lentivirus or EV control lentivirus. Two days
after transduction, the cells were reactivated by addition of TPA
and sodium butyrate for 48 h. The cells were harvested, and the
lysates were separated via SDS-PAGE and probed for endogenous
protein expression. Blotting confirmed the expression of vIRF1
and indicated that expression of vIRF1 resulted in a decrease in
endogenous cellular IRF3 levels and ISG15 conjugation compared
to the empty-vector control (Fig. 7A). To address the effect of
vIRF1 expression on reactivation, reactivation was quantified via
real-time PCR for message levels of a KSHV lytic gene, the Orf57
gene (27). At 48 h postreactivation, there was an 8-fold increase in
KSHV lytic gene transcription in vIRF1-expressing cells compared
to the empty-vector control (Fig. 7B). To further examine the
effect of vIRF1 expression on the relative production of infectious
virions, supernatants from reactivated BCBL1 cells expressing ei-
ther the empty-vector control or vIRF1 were used to infect 293
FIG 5 KSHV vIRF1 is ISG15 conjugated. (A) 293-TLR3 cells were transfected with the E1, E2, and E3 ligases for ISG15, FLAG-ISG15, and Myc-vIRF1 or control
empty vector (). Twenty-four hours after transfection, the cells were treated with poly(I·C) and harvested 24 h after treatment. The cell lysates were immu-
noprecipitated with anti-FLAG antibody-conjugated beads, followed by elution and resolution of eluate and input lysates via SDS-PAGE and immunoblotting
with the indicated antibodies. (B) 293-TLR3 cells were transfected with the E1, E2, and E3 ligases for ISG15, HA-ISG15, and FLAG-vIRF1 or control empty vector
(). Twenty-four hours after transfection, the cells were treated with poly(I·C) and harvested 24 h posttreatment. The cell lysates were immunoprecipitated with
anti-FLAG antibody-conjugated beads, followed by elution and resolution of eluate and input lysates via SDS-PAGE and immunoblotting with the indicated
antibodies. The data are representative of the results of three independent experiments.
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cells. Infection of 293 cells was quantified via real-time PCR for Orf57
DNA levels compared to a standard curve. The number of viral ge-
nomes was increased in 293 cells infected with supernatants from
vIRF1-expressing cells compared to empty-vector control cells (Fig.
7C). These data suggest that vIRF1 expression prior to reactivation
results in a decrease in ISG15 conjugation, reduced expression of
IRF3, and an increase in the production of infectious virions.
ISG15 knockdown prior to reactivation results in increased
KSHV production. As reactivation of latent KSHV was associated
with increased ISG15 expression and ISG15 is involved in antiviral
IFN responses (9), we hypothesized that ISG15 may affect KSHV
virion production. To allow ease of assessment of latent and lyti-
cally infected cells, we utilized an iSLK.219 cell line— cells of epi-
thelial origin that harbor the rKSHV.219 clone with GFP expres-
sion under a constitutively active promoter and RFP expression
under the control of the lytic PAN promoter (21). First, iSLK.219
cells were infected with a scrambled (scr) or ISG15-targeting
shRNA lentivirus. Efficient knockdown of ISG15 in iSLK.219 cells
FIG 6 Reactivation of KSHV increases ISG15 conjugation and IFN message. TREx BCBL1 cells expressing empty-vector control (pc) or RTA under a doxycycline
(Dox)-inducible promoter were treated with doxycycline for the number of hours indicated. (A) Cells were harvested and lysed prior to separation with
SDS-PAGE and immunoblotting with the antibodies indicated. (B) Doxycycline-treated TREx BCBL1 cells were harvested, RNA was extracted, and cDNA was
generated prior to quantification of IFN- and IFN- message levels by real-time (RT) PCR. (C) BCBL1 PEL cells were reactivated with sodium butyrate
treatment or vehicle control () for 24 or 48 h. The cells were harvested, and the lysates were resolved via SDS-PAGE, which was followed by immunoblotting
with the indicated antibodies. (D) BCBL1 PEL cells reactivated with sodium butyrate for 0 (), 24, 48, or 72 h were harvested. RNA was extracted, and cDNA was
generated prior to quantification of IFN- and IFN- message levels by RT-PCR. The data are representative of the results of three independent experiments, and
the values represent the means  the standard deviations of the means from triplicate biological replicates.
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was detected by immunoblotting (Fig. 8A). Seventy-two hours after
lentiviral infection, iSLK.219 cells were reactivated by addition of
doxycycline and examined for reactivation by observing RFP expres-
sion using fluorescence microscopy. As expected, cells that were not
reactivated exhibited no RFP expression (Fig. 8B). Cells that received
the scrambled shRNA exhibited less RFP expression following reac-
tivation than cells that were infected with the ISG15 shRNA lentivirus
(Fig. 8B and C). Reactivation was quantified via real-time PCR for
message levels of a KSHV lytic gene, the Orf57 gene (27). At 24 and 48
h postreactivation, there was a 7-fold and a 4-fold increase, respec-
tively, in KSHV lytic gene transcription in ISG15 knockdown cells
compared to a scrambled control (Fig. 8D).
To further examine the effect of ISG15 knockdown on the relative
production of infectious virions, supernatants were collected from
scrambled control and ISG15 shRNA lentivirus-infected and reacti-
vated iSLK.219 cells and used to infect 293 cells. Higher numbers of
GFP-positive 293 cells were seen after infection with supernatants
from ISG15 knockdown expressing cells than with supernatants from
the scrambled control (Fig. 8E and F). KSHV infection in 293 cells
was quantified via real-time PCR for Orf57 DNA levels compared to
a standard curve. The number of viral genomes was increased over
2-fold by supernatants from cells with knocked-down ISG15 levels
compared to scrambled control cells (Fig. 8G). These data suggest
that a reduction of ISG15 results in the production of more infectious
virions during lytic reactivation and that ISG15 conjugation of pro-
teins can suppress KSHV replication.
HERC5 knockdown prior to reactivation results in increased
KSHV production. As a reduction of ISG15 resulted in increased
replication of KSHV following reactivation, we next asked if
HERC5 was also necessary for maximal production of virions.
iSLK.219 cells were infected with a scrambled or HERC5-targeting
shRNA lentivirus. Efficient knockdown of HERC5 in iSLK.219
cells was detected by real-time PCR quantification of HERC5 mes-
sage levels (Fig. 9A). Seventy-two hours after lentiviral infection,
iSLK.219 cells were reactivated by addition of doxycycline and
examined for reactivation by observing RFP expression using flu-
orescence microscopy. As expected, cells that were not reactivated
exhibited no RFP expression (Fig. 9B). Depletion of HERC5 re-
sulted in increased RFP expression following reactivation com-
pared to cells expressing the nontargeting shRNA (Fig. 9B and C).
Supernatants were collected from reactivated cells depleted of
HERC5 or nontargeting control and used to infect 293 cells.
Higher numbers of GFP-positive 293 cells were seen after infec-
tion with supernatants from HERC5 knockdown expressing cells
than with supernatants from the scrambled control (Fig. 9D).
KSHV infection in 293 cells was quantified via real-time PCR for
Orf57 DNA levels compared to a standard curve. The number of
FIG 7 Expression of vIRF1 in PEL cells decreases ISG15 conjugation and
increases KSHV reactivation. BCBL1 cells were infected with lentivirus con-
taining EV control or Myc-vIRF1 for 48 h prior to reactivation with TPA and
sodium butyrate. (A) Cells were harvested 48 h after reactivation, lysed, and
resolved via SDS-PAGE, followed by immunoblotting with the indicated an-
tibodies.  react, no reactivation;  react, with reactivation. (B) Lentivirus-
transduced BCBL-1 cells were harvested 48 h after reactivation, RNA was ex-
tracted, and cDNA was generated prior to quantification of KSHV Orf57
message levels by real-time quantitative PCR (qPCR). (C) BCBL-1 cell super-
natants were harvested 48 h after reactivation and used to infect naive 293 cells,
and infected cells were harvested 48 h postinfection; DNA was isolated, and
Orf57 DNA levels were compared to a standard curve to assess the absolute
number of viral genomes by real-time qPCR. The data are representative of the
results of two independent experiments, and the values represent the means 
the standard deviations of the means from triplicate biological replicates.
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viral genomes was increased nearly 7-fold by infection with super-
natants from cells depleted of HERC5 compared to scrambled
control cells (Fig. 9E). These data suggest that a reduction of
HERC5, similar to ISG15, resulted in the production of more in-
fectious virions during lytic reactivation.
DISCUSSION
To elucidate the mechanisms of KSHV vIRF1 inhibition of type
I IFN, we performed an unbiased analysis of cellular proteins
that interact with vIRF1. Mass spectrometry identified the cel-
lular ISG15 E3 ligase, HERC5. Immunoprecipitation con-
firmed the interaction between vIRF1 and HERC5 and pin-
pointed the region between amino acids 224 and 349 of vIRF1
as the site of HERC5 association. Expression of vIRF1 resulted
in a global decrease in ISGylation of cellular proteins, including
decreased ISGylation of IRF3, which resulted in a decrease in
IRF3 protein levels. Furthermore, we found that the ISG15
pathway, not previously studied in the context of KSHV infec-
tion, played a role during viral reactivation. ISG15 conjugation
increased in response to reactivation, and knockdown of ISG15
resulted in increased levels of KSHV reactivation and produc-
tion of infectious KSHV particles.
FIG 8 Knockdown of ISG15 increases KSHV replication upon reactivation. (A) iSLK.219 cells were infected with scrambled control (scr) or ISG15 shRNA
lentivirus for 72 h. Cells were then lysed and subjected to SDS-PAGE and immunoblotting for the detection of ISG15 knockdown. (B) Seventy-two hours after
lentiviral infection with scrambled control or ISG15 shRNA lentivirus, iSLK.219 cells were reactivated for 48 h with doxycycline. Lytic virus was detected by RFP
expression via fluorescence microscopy. (C) RFP-expressing iSLK.219 cells were quantified by counting the cells in 4 random fields. (D) iSLK.219 cells were
infected with scrambled control or ISG15 shRNA lentivirus for 72 h prior to reactivation with doxycycline. Cells were harvested 24 or 48 h after reactivation, and
the RNA was isolated, reverse transcribed, and subjected to real-time qPCR to quantitate KSHV Orf57 message levels. (E) iSLK.219 cells were infected with
scrambled control or ISG15 shRNA lentivirus and reactivated for 48 h. The cell supernatants were harvested and used to infect naive 293 cells, and GFP expression
was quantitated 72 h postinfection. (F) GFP-expressing 293 cells were quantified by counting the cells in 5 randomly selected fields. (G) iSLK.219 cells were
infected with scrambled control or ISG15 shRNA lentivirus and reactivated for 48 h. The cell supernatants were then used to infect naive 293 cells. The infected
cells were harvested 48 h postinfection; DNA was isolated, and Orf57 DNA levels were compared to a standard curve to assess the absolute number of viral
genomes by real-time qPCR. The data are representative of the results of four independent experiments, and the values represent the means  the standard
deviations of the means from triplicate biological replicates. *, P 	 0.005; **, P 	 0.05 (Student’s t test).
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This is the first report to show the relationship between KSHV
and ISG15, although the ISG15 pathway has been shown to play a
role in viral replication during other viral infections. Knockdown
of HERC5 in 293 cells resulted in an attenuated interferon re-
sponse following Sendai virus (SeV) infection (8). Conversely,
overexpression of HERC5 increased interferon responses medi-
ated by SeV (8). Loss of Ube1L did not result in a change in New-
castle disease virus (NDV) infection, although Ube1L/ cells
produced higher levels of IFN- transcripts (28). The NS1 viral
protein of influenza virus is conjugated by ISG15, and this modi-
fication reduced influenza virus replication (26). Therefore,
ISG15 modification of NS1 contributes to cellular antiviral activ-
ity (26). In sum, ISG15 expression and conjugation have been
shown to inhibit the replication of SeV, Japanese encephalitis vi-
rus, NDV, avian sarcoma leucosis virus (ASLV), human papillo-
mavirus (HPV), dengue virus, HIV, vaccinia virus, VSV, influenza
virus, Ebola virus, HSV-1, and MHV-68 (29). Other viruses have
developed mechanisms to evade ISG15-mediated antiviral re-
sponses. For example, porcine reproductive and respiratory syn-
drome virus (PRRSV) encodes nonstructural protein 2 (nsp2),
which is an antagonist of ISG15 production and conjugation (30).
Together, these data suggest that coevolution has occurred be-
tween viral evasion of ISG15 and IFN responses and host efforts to
block viral infection and reproduction.
Here, we established that KSHV vIRF1 alters the cellular ISG15
posttranslational modification system. Other vIRFs have been
FIG 9 Knockdown of HERC5 increases KSHV replication upon reactivation. (A) iSLK.219 cells were infected with scrambled control or HERC5 shRNA lentivirus for
72 h prior to harvesting for detection of HERC5 knockdown through real-time qPCR. (B) Seventy-two hours after lentiviral infection with scrambled control or HERC5
shRNA lentivirus, iSLK.219 cells were reactivated for 48 h with doxycycline. Lytic virus was detected by RFP expression via fluorescence microscopy. (C) RFP-expressing
iSLK.219 cells were quantified by counting the cells in 6 randomly selected fields. (D) iSLK.219 cells were infected with scrambled control or ISG15 shRNA lentivirus and
reactivated for 48 h. The cell supernatants were harvested and used to infect naive 293 cells, and infection was detected by GFP expression via fluorescence microscopy
48 h postinfection. (E) iSLK.219 cells were infected with scrambled control or ISG15 shRNA lentivirus and reactivated for 48 h. The cell supernatants were then used to
infect naive 293 cells. The infected cells were harvested 48 h postinfection; DNA was isolated, and Orf57 DNA levels were compared to a standard curve to assess the
absolute number of viral genomes by real-time qPCR. The data are representative of the results of three independent experiments, and the values represent the means 
the standard deviations of the means from triplicate biological replicates. *, P 	 0.01 (Student’s t test).
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shown to play a role in posttranslational modifications, as well.
Specifically, expression of vIRF3 increases the levels of SUMO2
ubiquitination-modified promyelocytic leukemia (PML) gene
product oncogenic domains (PODs) (31). Furthermore, vIRF3 is
covalently conjugated to SUMO1 and SUMO2 in vitro and in
KSHV latently infected B cells (32). vIRF3 is also capable of inhib-
iting SUMOylation of the pRb proteins pRb, p107, and p130 (33).
We recently showed that vIRF1 affects phosphorylation of STING
as well (34). These data suggest that one of the mechanisms of
action of the vIRF proteins may be through alteration of cellular
posttranslational modifications and that further study of all vIRFs
in this area is warranted.
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